The frequency of grade 2 or higher adverse events was higher in participants in the long-acting cabotegravir group (n=75 [80%]) than in those in the placebo group (n=10 [48%]; p=0·0049), mostly due to injection
1 Discuss the two injection dosing frequency options with patients prior to starting this medication regimen and decide which injection dosing frequency would be the most appropriate option.1 Inform patients that cabotegravir and rilpivirine can remain in the body for up to >12 months after ...
CAB was still detectable 52 weeks after the last injection in 14% of subjects13. Such a long pharmacologic drug tail can conceivably create opportunities for rapid resistance selection if drug levels are not sufficiently high to prevent infection but are high enough to select for drug-resistant vi...
In ATLAS-2M, the type and frequency of adverse reactions reported in participants receiving long-acting cabotegravir and rilpivirine once monthly or every two months for 48 weeks were similar. In the every-two-month arm, rates of serious adverse events (SAEs: 27/522[5.2...
CABENUVA can be injected monthly or every 2 months [seeDOSAGE AND ADMINISTRATION]. Healthcare providers should discuss these 2 dosing options with the patient prior to starting CABENUVA and decide which injection dosing frequency would be the most appropriate option for the patient [seeADVERSE REACTIO...
Cabotegravir extended-release injectable suspension is a white to light pink free-flowing suspension for intramuscular injection in a sterile single-dose vial. Each vial delivers 600 mg/3 mL (200 mg/mL) of cabotegravir and mannitol (105 mg), polyethyleneglycol (PEG) 3350 (60 mg), polysorbat...
1.A method of treating HIV-1, comprisingregularly administering intramuscular injections of cabotegravir or a salt thereof and rilpivirine or a salt thereof,subsequent to at least one said intramuscular injection of each of cabotegravir or a salt thereof and rilpivirine or a salt thereof, disconti...
Duration of therapy ranged from 1 to 1020 days (average 579 days) since first injection and longer duration of therapy weakly correlated with prevalence of blips or viremia. 92% of doses have been administered within the allowable 14-day treatment window. There was no significant difference ...
Results were reported as median (interquartile range [IQR]) or frequency (percentage). Cumulative probabilities of TD were estimated using Kaplan-Meier curves. RESULTS. We evaluated 514 participants; 467 (90.9%) were male, and their median age (IQR) was 49 (40–56) years. At the time of...
Participants were monitored after the first injection until the date of CAB+RPV discontinuation, death, or last visit to the center. Results We enrolled 102 PLWH. We grouped participants based on their duration of follow-up: all completed 4 weeks; 77 remained for 12 weeks; 60 for 28 weeks;...